53 completed, 9 recruiting, 5 withdrawn, 4 terminated. 29 Phase 1, 22 Phase 2, 8 Phase 3, 7 Not applicable, 1 Early Phase 1.
Follow Olfactory Nerve Diseases: new trials by email Literature Review of Olfactory Nerve Diseases trials Research Report on Olfactory Nerve Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2 Study Of Zanzalintinib For Patients With Recurrent Or Metastatic Olfactory Neuroblastoma Zanzalintinib - Metastatic Olfactory Neuroblastoma | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 16 | 2026-10-01 | 2026-10-05 |
| Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors Tarlatamab, Concurrent Radiation Therapy, Sequential Radiation therapy - Melanoma, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Recruiting | University of Arizona | 30 | 2025-09-08 | 2026-10-06 |
| [212Pb]VMT-Alpha-NET in Metastatic or Inoperable Somatostatin-Receptor Positive Gastrointestinal Neuroendocrine Tumors, Pheochromocytoma/Paragangliomas, Small Cell Lung, Renal Cell, and Head and Neck Cancers [212Pb]VMT-alpha-NET, [203Pb]VMT-alpha-NET, 68Ga-DOTATATE - Sinonasal Neuroendocrine Carcinoma, Nasopharyngeal Carcinoma | Phase 1 | Recruiting | National Cancer Institute (NCI) | 120 | 2025-08-19 | 2026-10-06 |
| An International Study on Pediatric Patients With Rare Tumors. Paraganglioma/ Phaeochromocytoma, Melanoma and Other Malignant Neoplasms of Skin | Recruiting | Azienda Ospedaliera di Padova | 6250 | 2025-01-25 | 2025-07-18 | |
| A Phase II Study of Rivoceranib for Patients With Recurrent or Metastatic Olfactory Neuroblastoma Rivoceranib - Metastatic Olfactory Neuroblastoma, Recurrent Olfactory Neuroblastoma | Phase 2 | Withdrawn | M.D. Anderson Cancer Center | 2024-11-01 | 2025-01-10 | |
| Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed). Olaparib; 177Lu-DOTATATE - Solid Tumor Cancer, Medulloblastoma | Phase 1 / Phase 2 | Recruiting | Fundación de investigación HM | 25 | 2024-09-20 | 2026-06-04 |
| Enasidenib in IDH2-Mutated Malignant Sinonasal and Skull Base Tumors Enasidenib - Metastatic Chondrosarcoma, Locally Advanced Chondrosarcoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 40 | 2024-03-04 | 2026-10-16 |
| Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma (ESICON) Gemcitabine+Cisplatin(GP); Cyclophosphamide+Etoposide+Cisplatin(CEP) - Olfactory Neuroblastoma | Phase 2 | Recruiting | Hongmeng Yu | 25 | 2024-03-01 | 2024-02-13 |
| Phase 2 Study of Bintrafusp Alfa in Recurrent/Metastatic Olfactory Neuroblastoma (BARON). Bintrafusp alfa/M7824, Ibuprofen, PET scan - Olfactory Neuroblastoma, Esthesioneuroblastoma | Phase 2 | Completed | National Cancer Institute (NCI) | 11 | 2022-06-21 | 2025-08-08 |
| A Natural History Study of Children and Adults With Olfactory Neuroblastoma Olfactory Neuroblastoma, Esthesioneuroblastoma | Recruiting | National Cancer Institute (NCI) | 525 | 2022-06-02 | 2026-10-16 | |
| Intranasal Injection of PRP Versus Saline for Treatment of Olfactory Dysfunction Injection into olfactory cleft - Olfactory Disorder, Olfaction Disorders | Not applicable | Completed | Stanford University | 30 | 2021-06-22 | 2023-03-13 |
| 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors. Ga68-DOTATATE-PET/MRI - CNS Tumors, Meningioma | Phase 4 | Recruiting | Weill Medical College of Cornell University | 200 | 2019-09-04 | 2026-10-30 |
| Long-Term Longitudinal QoL in Patients Undergoing EEA Pituitary Tumor, Meningioma | Active not recruiting | Ohio State University | 400 | 2019-07-16 | 2026-05-20 | |
| Impact of Nasoseptal Flap Harvest Technique on Olfaction Following Endoscopic Transsphenoidal Pituitary Surgery Electrocautery versus scalpel - Pituitary Tumor, Surgery | Not applicable | Unknown | Unity Health Toronto | 20 | 2019-02-25 | 2019-03-15 |
| A Clinical Trial of Endoscopic Surgery Followed by Chemotherapy and Proton Radiation for the Treatment of Tumors in the Sinus and Nasal Passages Cisplatin, Adjuvant Proton Radiotherapy, Endoscopic Resection - Paranasal Sinus Cancer, Nasal Cavity Tumor | Phase 2 | Completed | Memorial Sloan Kettering Cancer Center | 3 | 2017-09-01 | 2025-05-16 |
| Esthesioneuroblastoma: Outcomes After Treatment Esthesioneuroblastoma, Olfactory | Withdrawn | Ricardo L. Carrau, MD | 2015-09-01 | 2021-02-11 | ||
| 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy 18F-fludeoxyglucose (18F-FDG), 18F-FPPRGD2 - Adult Giant Cell Glioblastoma, Adult Glioblastoma | Phase 1 / Phase 2 | Completed | Sanjiv Sam Gambhir | 25 | 2013-03-04 | 2019-10-03 |
| Intensity-Modulated or Proton Radiation Therapy for Sinonasal Malignancy Proton radiation therapy, Intensity-modulated radiotherapy - Adenoid Cystic Carcinoma, Squamous Cell Carcinoma | Not applicable | Unknown | Massachusetts General Hospital | 45 | 2011-07-12 | 2023-09-21 |
| Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy doxepin hydrochloride, placebo - Head and Neck Cancer, Mucositis | Phase 3 | Completed | Alliance for Clinical Trials in Oncology | 155 | 2010-12-01 | 2017-08-09 |
| Potential Biomarkers for Bevacizumab-Induced High Blood Pressure in Patients With Solid Tumor laboratory biomarker analysis, questionnaire administration - Breast Cancer, Cardiovascular Complications | Terminated | Vanderbilt-Ingram Cancer Center | 8 | 2010-03-01 | 2012-02-27 |
Showing 20 of 76. Sign in to see all of them.
Esthesioneuroblastoma, Olfactory (74) · Squamous Cell Carcinoma of Head and Neck (54) · Salivary Gland Neoplasms (47) · Head and Neck Neoplasms (42) · Carcinoma, Non-Small-Cell Lung (31) · Breast Neoplasms (26) · Colonic Neoplasms (21) · Lung Neoplasms (17) · Prostatic Neoplasms (17) · Small Cell Lung Carcinoma (17) · Carcinoma, Ovarian Epithelial (15) · Urinary Bladder Neoplasms (15) · Pancreatic Neoplasms (14) · Rectal Neoplasms (14) · Breast Neoplasms, Male (13)
Cranial Nerve Diseases (76) · Nervous System Diseases (76) · Neoplasms by Histologic Type (74) · Neoplasms, Germ Cell and Embryonal (74) · Neoplasms, Glandular and Epithelial (74) · Neoplasms, Nerve Tissue (74) · Neoplasms, Neuroepithelial (74) · Neuroectodermal Tumors (74) · Neuroblastoma (72) · Neuroectodermal Tumors, Primitive (70) · Neoplasms by Site (69) · Neuroectodermal Tumors, Primitive, Peripheral (68) · Neoplasms (65) · Carcinoma (62)
Docetaxel (8) · Radiotherapy (6) · Cisplatin (5) · Filgrastim (5) · Bevacizumab (3) · Capecitabine (3) · Cetuximab (3) · Chemotherapy, Adjuvant (3) · Erlotinib Hydrochloride (3) · Etoposide (3) · Radiotherapy, Intensity-Modulated (3) · Acupuncture Therapy (2) · Carboplatin (2) · Cyclophosphamide (2) · Gemcitabine (2)
National Cancer Institute (NCI) (14) · Memorial Sloan Kettering Cancer Center (5) · Alliance for Clinical Trials in Oncology (4) · Vanderbilt-Ingram Cancer Center (4) · Case Comprehensive Cancer Center (3) · Fox Chase Cancer Center (2) · M.D. Anderson Cancer Center (2) · National Institutes of Health Clinical Center (CC) (2) · University of Arizona (2) · University of Miami (2) · Vanderbilt University (2) · Abramson Cancer Center at Penn Medicine (1) · Azienda Ospedaliera di Padova (1) · Cancer Trials Ireland (1) · City of Hope Medical Center (1)
United States (61) · Canada (4) · China (1) · Germany (1) · Ireland (1) · Italy (1) · Netherlands (1) · Puerto Rico (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Charalampos Floudas, M.D. (3) · Scot C. Remick, MD (3) · Barbara Murphy, MD (2) · Barry L. Gause, MD (2) · Lionel D. Lewis, MD (2) · A. Bapsi Chakravarthy, MD (1) · Alain Mita (1) · Ann Marie Flores, Ph.D. (1) · Annie W Chan, MD (1) · Antonius Miller (1) · Arnold M. Markoe, MD, ScD (1) · Barbara Burtness (1) · Beverley de Valois, PhD LicAc (1) · Brian P. Monahan, MD, FACP (1) · Brittany Holmes (1)
PMID 12525530, PMID 15033677, PMID 17545536, PMID 18470481, PMID 20145168, PMID 20406930, PMID 20407240, PMID 21791630, PMID 21917515, PMID 22480131, PMID 23188068, PMID 23868427, PMID 24733799, PMID 25965900, PMID 26062933, PMID 26611425, PMID 27020837, PMID 30850872, PMID 35275019, PMID 35661809, PMID 36507615, PMID 38553990, PMID 39500789, PMID 42307670
P30CA068485 (5), P30CA043703 (3), U10CA031946 (3), U01CA062502 (2), N01CM62202 (1), P01CA021239 (1), P30CA006516 (1), P30CA006927 (1), P30CA006973 (1), P30CA008748 (1), P30CA014520 (1), P30CA016087 (1), P30CA016672 (1), P30CA023074 (1), P30CA023108 (1)